Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics

Biological Psychiatry

Volumn 39, Issue 2, 1996, Pages 135-138

  Verghese, Cherian ^a   DeLeon, Jose ^a   Nair, Chand ^a   Simpson, George M ^b  

^a Norristown State Hospital   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Anticholinergics; Clozapine; Dopamine receptors; Neuroleptics; Risperidone; Substance withdrawal syndrome

Indexed keywords

4 AMINOBUTYRIC ACID; CLOZAPINE; DOPAMINE RECEPTOR; RISPERIDONE;

DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; SHORT SURVEY; SIDE EFFECT;

EID: 0030023357     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00215-4     Document Type: Note

References (28)

1. Alphs LD, Lee HS (1991): Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 52:346-348.
2. Ashton CH, Rawlins MD, Tyrer SP (1990): A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry 157:232-238.
3. Borison RL, Diamond BI, Sinha D, Gupta RP, Prince Ajiboye A (1988): Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24:260-263.
4. Chouinard G (1990): Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 5:21-33.
5. Chouinard G, Jones BD (1980): Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137:16-21.
6. Coward DM (1992): General pharmacology of clozapine. Br J Psychiatry (supplement) 17:5-11.
7. Coward DM, Imperato A, Urwyler S, White TG (1989): Biochemical and behavioral properties of clozapine. Psychopharmacology 99:S6-S12.
8. Dilsaver SC, Feinberg M, Greden JF (1983): Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 140:249-251.
9. Dilsaver SC, Greden JF (1984): Antidepressant withdrawal phenomena. Biol Psychiatry 19:237-256.
10. Ekblom B, Eriksson K, Lindstrom LH (1984): Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology 83:293-294.
11. Eklund K (1987): Supersensitivity and clozapine withdrawal. Psychopharmacology 91:135.
12. Farde L, Wiesel F-A, Nordstrom A-L, Sedvall G (1989): D1 and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31.
13. Frey JM, Ticku MK, Hoffman RD (1987): GABAergic supersensitivity within the pars reticulata of the rat substantia nigra following chronic haloperidol administration. Brain Res 425: 73-84.
14. Gale K (1980): Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283:569-570.
15. Gerlach J (1991): New antipsychotics: Classification, efficacy, and adverse effects. Schizophr Bull 17:289-309.
16. Jellinek T, Gardos G, Cole J (1981): Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 138:1567-1571.
17. Kuha S (1977): The consequences of sudden stopping of clozapine in Finland. In VIth World Congress of Psychiatry, Honolulu, Am Psychiatr Assoc Abstracts 813:153.
18. Leysen JE, Janssen PM, Megens AA, Schotte A (1994): Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55(suppl):5-12.
19. Marco E, Mao CC, Revuelata A, Peralta E, Costa E (1978): Turnover rates of gamma-aminobutyric acid in substantia nigra, N. caudatus, globus pallidus and N. accumbens of rats injected with cataleptogenic and non-cataleptogenic antipsychotics. Neuropharmacology 17:589-596.
20. O'Dell SJ, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF (1990): Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6:146-153.
21. Perenyi A, Kuncz E, Bagdy G (1985): Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology 86:244.
22. Simpson GM, Amin M, Kunz E (1965): Withdrawal effects of phenothiazines. Compr Psychiatry 6:347-351.
23. Simpson GM, Lee JH, Shrivastava RK (1978): Clozapine in tardive dyskinesia. Psychopharmacology 56:75-80.
24. Simpson GM, Varga E (1974): Clozapine - A new antipsychotic agent. Curr Ther Res 16:679-686.
25. Snyder S, Greenberg D, Yamamura HI (1974): Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31:58-61.
26. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
27. Thaker GK, Nguyen JA, Strauss ME, Jocobson T, Kaup BA, Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
28. Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991): Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614.